Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rx Reimportation Passes House; CBO Score May Keep It Out Of Medicare Rx

Executive Summary

The Congressional Budget Office's determination that prescription drug reimportation would not provide any cost savings could help House/Senate Medicare conferees distance themselves from the House's positive vote on reimportation

Related Content

Rx Import Debate Launches In Senate With Introduction Of Four Bills
HHS Rx Price Negotiations Could Gain Bipartisan Support, Consultant Says
Reimportation Limits Remain In Medicare Agreement; HHS Study Requested
Rx Imports: Pfizer Says Political Bark Is Worse Than Commercial Bite
Medicare Rx Must Address “Anger” Over Drug Prices, AARP’s Rother Says
Rx Reimportation Could Help PBMs Reduce Costs, Caremark SEC Filing Says
Reimportation Likely In 2003, Merck Says, But HHS Certification Should Stay
Rx Pricing Debate Must Be Framed As Trade Issue, Pfizer CEO Says
Risk management programs and reimportation
FDA Generic Rx Reforms Contribute To Medicare Budget Squeeze



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts